<SEC-DOCUMENT>0001564590-18-023788.txt : 20181105
<SEC-HEADER>0001564590-18-023788.hdr.sgml : 20181105
<ACCEPTANCE-DATETIME>20181001172830
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001564590-18-023788
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20181001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IRIDEX CORP
		CENTRAL INDEX KEY:			0001006045
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770210467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6509404700

	MAIL ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irix-corresp.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gkumseckhzqc000001.jpg" title="" alt="" style="width:133px;height:125px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">September 20, 2018</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Via Overnight Mail</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Cecilia Blye, Chief, Office of Global Security Risk<br />Ms. Amanda Ravitz, Assistant Director, Division of Corporation Finance</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Jennifer Hardy, Special Counsel<br />United States Securities and Exchange Commission<br />100 F Street, N.E.<br />Washington, D.C. 20549</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.35%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.35%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Re:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">IRIDEX Corporation<br />Form 10-K for the Fiscal Year Ended December 30, 2017<br />Filed March 14, 2018, Mail Stop 4628<br />File No. 000-27598</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Ms. Blye, Ms. Ravitz, and Ms. Hardy:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On behalf of IRIDEX Corporation (&#8220;<font style="font-weight:bold;">we</font>,&#8221; the &#8220;<font style="font-weight:bold;">Company</font>,&#8221; or &#8220;<font style="font-weight:bold;">IRIDEX</font>&#8221;), we submit this letter in response to comments from the staff of the Securities and Exchange Commission (the &#8220;<font style="font-weight:bold;">Staff&#8221;</font>) received by letter dated August 30, 2018 relating to the Company's Form 10-K for the fiscal year ended <font style="font-weight:bold;">December 30, 2017</font> (the &#8220;<font style="font-weight:bold;">Form 10-K</font>&#8221;) filed on March 14, 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this letter, we recite the comments from the Staff in italicized type and follow each comment with the Company's response.&nbsp;&nbsp;Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:7.35%;text-indent:7.35%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>In your letter to us dated August 17, 2015, you discussed contacts with Syria.&nbsp;&nbsp;You disclose sales in the Middle East and Africa, regions that include Syria and Sudan. Your disclosure does not discuss contacts with those countries.&nbsp;&nbsp;As you know, Syria and Sudan are designated by the State Department as state sponsors of terrorism and are subject to U.S. sanctions and/or export controls.&nbsp;&nbsp;Please describe to us the nature and extent of any past, current, and anticipated contacts with Syria and Sudan since the 2015 letter, including with their governments, whether through subsidiaries, distributors, resellers, affiliates, or other direct or indirect arrangements.&nbsp;&nbsp;Please also discuss the materiality of any contacts, in quantitative terms and in terms of qualitative factors that a reasonable investor would deem important in making an investment decision.&nbsp;&nbsp;Tell us the approximate dollar amounts of any revenues, assets and liabilities associated with Syria and Sudan for the last three fiscal </p>
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States Securities and Exchange Commission<br />September 20, 2018<br />Page 2</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:7.35%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">years and the subsequent interim period.&nbsp;&nbsp;Address for us the potential impact of the investor sentiment evidenced by divestment and similar initiatives that have been directed toward companies that have operations associated with U.S. - designated sta</font><font style="font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">te sponsors of terrorism.&nbsp;&nbsp;Finally, tell us whether any contacts involved dual use products and, if so, the nature of the dual uses.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a leading worldwide provider of therapeutic and medical-based laser systems and delivery devices used to treat eye diseases in ophthalmology.&nbsp;&nbsp;We sell internationally through approximately 70 independent distributors into 100 countries.&nbsp;&nbsp;Our customers are doctors, hospitals, healthcare practices or humanitarian organizations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the August 17, 2015 response letter, the Company has engaged in the sale of ophthalmology products to Syria.&nbsp;&nbsp;These products used to treat eye disease are classified as EAR99 by the Department of Commerce and we have obtained export licenses from the Department of Commerce, Bureau of Industry and Security prior to completing such sales.&nbsp;&nbsp;We distribute these products in Syria through a distributor, Pioneers for Medical Equipment, and have done so since 2006.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since 2015, our sales to Syria have been as follows:</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom"  style="width:15.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales</p></td>
<td valign="bottom"  style="width:68.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  style="width:15.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0</p></td>
<td valign="top"  style="width:68.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Qty 1: warranty replacement of SLx Laser System</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  style="width:15.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$89,650 </p></td>
<td valign="top"  style="width:68.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Qty 1: SL Laser System; Qty 1: SLx Laser System; Qty 1: Cyclo G6; Qty 1: IQ 532 Laser System; Qty 1: Operating Microscope Adapter; Qty 2: DioPexy; Qty 1: Slit Lamp Adapter; Qty 1: Slit Lamp with table; Qty 3: Eye Safety Filters; Qty 7: prs. Safety Glasses; Qty 3: boxes G-Probe; Qty 5: boxes MicroPulse P3 devices; Qty 8: boxes EndoProbe</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  style="width:15.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $192,250 </p></td>
<td valign="top"  style="width:68.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Qty 3: SL Laser Systems; Qty 1: TX Laser Systems; Qty 1: IQ 532 Laser System; Qty 2: IQ 577 Laser Systems; Qty 4: slit lamps and tables; Qty 1: Slit Lamp Adapter; Qty 3: TxCell Scanning Laser Delivery Systems; Qty 4: Eye Safety Filters; Qty 4: prs Safety Glasses; Qty: 18 boxes EndoProbe; Qty 2: boxes G-Probe; Qty 1: Footswitch</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through 8/31/18</p></td>
<td valign="top"  style="width:15.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $18,920 </p></td>
<td valign="top"  style="width:68.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Qty 1: SL Laser System; Qty 1: box G-Probe; Qty 3: boxes EndoProbe; Qty 1: Eye Safety Filter; Qty 3: prs Safety Glasses; Qty 1: slit lamp observation tube; Qty 1: slit lamp beamsplitter</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate future business dealings in Syria to follow this pattern.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States Securities and Exchange Commission<br />September 20, 2018<br />Page 3</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since 2015, w</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e have</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> had</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> no sales </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Sudan</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and no contacts with entities or individuals in Sudan, including the Sudanese government.&nbsp;&nbsp;We</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> do not anticipate future business dealings</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in Sudan</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contacts with Syria have all been to Pioneers for Medical Equipment and not with the Syrian government.&nbsp;&nbsp;These contacts are not material in qualitative or quantitative terms and we do not consider these contacts a material investment risk for our security holders.&nbsp;&nbsp;Our approximate revenues for 2015, 2016, 2017, and through August 31, 2018 were $41.8 million, $46.2 million, $41.6 million, and $26.7 million, respectively.&nbsp;&nbsp;Sales to Syria per year expressed in terms of a percentage of overall revenues per year were 0.00%, 0.19%, 0.46%, and 0.07%, respectively, during 2015, 2016, 2017, and through August 31, 2018.&nbsp;&nbsp;Apart from the sales to Syria described above, the Company does not own any assets or liabilities associated with either country.&nbsp;&nbsp;As such, the contacts with Syria are not material to the Company in quantitative terms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our sales in Syria are to doctors, hospitals, or healthcare practices to help improve the lives of individual patients and our products have no intended non-medical use.&nbsp;&nbsp;We are not aware of any of the doctors we sell to being employed by the Syrian government.&nbsp;&nbsp;Furthermore, our products do not have a dual use.&nbsp;&nbsp;Additionally, we obtained export licenses for all of our sales into Syria prior to completing any particular sale.&nbsp;&nbsp;Therefore, we do not consider these corporate activities as having a negative impact on the Company's reputation and/or share value and we do not consider these contacts to be qualitatively material to investors wishing to avoid investment in companies that do business with U.S.-designated state sponsors of terrorism.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, the products sold to Syria are classified as EAR99 under the Department of Commerce Control List and have no material non-medical use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with IRIDEX&#8217;s responses to the Staff&#8217;s comments, we acknowledge that we are responsible for the adequacy and accuracy of the disclosure in our filings with the Securities and Exchange Commission, Staff comments or changes to disclosure in response to Staff comments do not foreclose the Securities and Exchange Commission from taking any action with respect to such filings, and we may not assert Staff comments as a defense in any proceeding initiated by the Securities and Exchange Commission or any person under the federal securities laws of the United States. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please acknowledge receipt of this letter by stamping the enclosed duplicate of this letter and returning it to the undersigned in the envelope provided.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States Securities and Exchange Commission<br />September 20, 2018<br />Page 4</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.35%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should you desire to discuss these comments, please contact </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philip H. Oettinger</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation at your earliest convenience</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">He</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> can be reached at (650) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">565-3564</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and I may be reached at (650) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605-8782</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:52.39%;text-indent:6.43%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:42.87%;">
<tr>
<td style="width:3.84%;"></td>
<td style="width:1.79%;"></td>
<td style="width:37.24%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;"><a name="_Hlk526156484"></a>&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William M. Moore</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William M. Moore</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IRIDEX Corporation President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.21%;"></td>
<td style="width:93.79%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cc:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philip H. Oettinger, Esq.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wilson Sonsini Goodrich &amp; Rosati, P.C.</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>gkumseckhzqc000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gkumseckhzqc000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "^ ,H# 2(  A$! Q$!_\0
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M.M[N+_6V=U'Y<R<=QT(]U)'O6Y04%%%% !1110 4444 %%%% !1110 4444
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MB\J>".6/'W74$5FU9V-4TU=',W4_A7PC<"XU&]B%].=ZR7+&6=QT^4<L%^@
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MIBNFK-T#3AI'A_3=.4DBTM8X<GK\J@?TK2KB/4"BBB@ HHHH **** "BBB@
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M>1?D.2,Q_P"?>M6UNX+VUBN;:020RJ'1UZ,#T-.[[@TGN/2)(T5$4*JC 4#
M ]*Y'Q!X!L=3N#J-A--I^J(A\N:!RH)Y^\!]:[#-1"Y@>=X%F0S( 6C##<H/
M0D=J$[/0&D]SSP^,O$?A2Z2+Q;IHGLFQC4+!253M\R_7/H<=C6WXAUW3-2\
M:E?VEW;W%K+;.BMNX+$8 /<')Z=:Z>:.*:!XIE5HV!#*P!!%?/WC:+1K37Y;
M30)?]%8"29(I=T/F=!CMP,_3-7!*<DC&K/V4')G-I*(ADJ6#?+@(S>W 'M7<
M_#_3UGTHP2%DDUW4E4!.";>V7<S?[I8%?^!=^*X66.>Y:&SLE+7<TJQ11\$M
M(&  !!X'/Z9X%>X>![!)[R2\6!([72HCI-D5 (E5"#)+GW88&/0U6(J<T[+I
MH9X2DX4]=V=Y2T45B=84444 %%%% !1110 4444 %0W-O#=6TMO<1)+#*I1X
MY%!5E/!!'<5-10!Y!KWA0W<?_",W#A+B!GET>Y< >?!]YK?Y2.4^7KVP?6O*
M(IC:X2==L?0Y)^4Y/8_YZ5]0:_H%KK]FD,YDCDAD$L$\3E7AD'1@1]>G0C@U
MY)KV@7?B34KBPOXH;/Q1;G>BQKLM]1BP?WD9.</V*Y/2JA4E!J2,JE*,TTSE
M['5]1TN-A8WTT R/]7C'?H,>YK7\+ZX$\8:=>ZW?2/!$SX>7<P5BNT'VYQR:
MXE+F6TNVL[B)E9':,@H0R$9Z@X]#5_S!*-P*E2."!U%=\(TZL6X[L\J<Z]":
M4V[+\CZD$B>3YFY=F-VX'C'K7E?B7QA;^*/$FD^&M/,CZ?)?(MY*K86X4'.U
M2#G;P<YQGW%><"[O%C$:7<RQ@;=HD.,8Z8^A-.T^Z.EZI8W]N-TEK*LBA@#N
MP1QUZ]>XK*.$:NVSH>/C)I)6/H>?_D8=/QT^S7' /O'[_P!*X3_A)AX)\?ZE
MIUZS_P!DWSK<QD#(@=Q@D?[)()('?D=ZZX:UIUU/I^JQW"FS:RN)?-SPH!BS
MGL".E>(^*-6.O>);V^#,86DVP\8P@X'?\?QK&C2YY69TXFLJ<.9,^BK:Y@O;
M5)[:9)89!E)$.0:\.^(FK6]SXS^TZ1='S8H4BEF@;JP8G (ZXS^E<L)KQ;06
MZ7DP@Q@Q>8=F.3TSCDFH3M4&0N-QR3D^_?UKHIX.TE*3V.*KC^>'+%69?N]?
MUF]M5MKO4[F6)$VX9^H]\]:QKQQ9%EF5E8$"5'SD  Y_D/SHNK]8Q^[=2S=3
MMSP>,Y'?GI[5UOA+PG&\UKJ>IV/VV\NG$FG:8YV[US@SS@@[4!YQW]#2JU80
M3C3-*%&K4:G6>W0L>"](O;1HKM8C_P )#JP1+*-E5C86QX>Y<=!D @#&3@#G
MFO<M+L+?2],MK"U7;!;QK&@SG@#'-9GA[PVND37-_<3M=:G>A/M,S?= 4<(@
M_A09.!6]7$>D%%%% !1110 4444 %%%% !1110 4444 %9VL:-9ZS9^1=(P9
M3NBEC<I)$V,;D8<J16C10!X_XD\-VZ1>5XICF2;<4B\0VT7R2(,%1<!3E6S_
M !8 .!R,XKSS4_#&J:&J7.V2:U*$B:U'FPR $[?F&0.O(X_2OJ(KGK7,W?@N
MU%Y)?Z/<R:3>R#;*T"AHY1G.'C8%3]0 >3S0I2B[QW(<(RTDKH^<4O'1(FEB
M+9P&9>.3GUZ]#^E6/M:_9?./"G(!;CG _P :]9USP?J4[ ZCX<TS5E7 $^ER
M&RG],E&)4X_WJYN#P3H\L:QW-KXLTPX^1)K'S@&P <-$K'G'7@UT?7)Q5FCC
ME@*3=UH<D=1DCL18B[9;57DQ&7VCG[PQGH2H)]Q4)DCBB8MC"9!/7TS6]=>$
M="M[F&VN?%%TEP6 6&31+G<S,?EXQGN<?A5\>"-)@%OBX\1W\Y!>1;729$Z'
MH#* 5SQW/3)JI8Q+51)^H7>LKHX\W(D641NFY4R-[8#9P /UY^E7-/TW5O$K
MM;Z1:R2#>5E9!B%% 3[SD\8.3CK7<Z!X%(-LUOX.;[VYKG7KS)'<?N8QC&>U
M=Q:>!_M%Q#<Z]?OJ#0_-':1KY-K&<YR(U^]V^]FLIXBI-;F]+#4Z;]U'GOAK
MPA9P.)=,M_[=UE&"K?;/+LK$Y()4G_6,I.1P1QVKUC0?#D.C>;<27$U[J5PJ
MBYO;@Y>7;T&.BJ,G"CCFM:&"."-8XHUCC4855& !["I*R.HY;QCXM;PU9J;:
M!+BZ)5FCD8JJ1E@NXXYZD  5)X/\5'Q-8.TT M[N$(944Y1E<$JRGNI [\]:
ME\3>%4\1K:G[6UL\$BN<(&650P;:PX)&5'>H_"/A"/PK!<J+V:[EN"FZ23("
MJJX55!)P ,T =+1110 4444 %%%% !16;KNM0:!I4NHW,4TL494%85!8Y( Z
MD>M<<?C#H(;;_9^JEO3RH_\ XN@+GH=%>?\ _"W="#;6LM34Y[QQ\^F/GY[?
MG5F7XHZ%#8V%VUOJ!CO8C+'B$94 D$'+=>#TS19@=O17GP^+_AX@'[+J6,9/
M[E>/_'O\XI6^+_AY&*_9M0+C^$)'G/XO3LQ71Z!17#VGQ8\+7,L<4LUS:/(<
M#[3 54=>K#*CIZ]Q6KJGC71=-T:/5EN!>VDD@B5K-TDR2I;^\!T'K2>@)I['
M1T5YY_PN+P]G!M-3W8!*B%2P!&<X#?3\ZD_X6]X<\Q4\J^!9@N3$HQEMH/WN
MG]* 33V.^I"*X[5_B;H6BZI<:?<QWK36[B.0QPY4$A2,'//##]:JK\6_#IQN
MBOT)[-$H/3/]ZBP71W6T>@I<#TK@F^+WAU5W&WO_ $P$0G_T.K-O\5?"LQQ-
M=3VIW!?W]NP R"<D@$#IW-%@NCM<4"JFGZI8ZK:K<Z?=0W,+='B<,*RO$OC+
M2_"AMQJ7G_OPQ3RDW?=QGN/4?G0.YT-%<$/BYX9*Y!O.I&/)Y!&>HS[?J*4_
M%OPR.-UYTR/W'!YQZU7++L3SQ[G>45PG_"VO# !)>["@\GR?3KWKH$\5::WA
MA?$.Z06#('RRX8 G'3ZTFFMQII[&W17!_P#"V_#.W<WVU5XY:#'!QSU]^?QJ
M?2_BAX>U?5[73+8W?VBZD,<>^'"Y 8G)S_LFCE8N97L=K14%Y=Q6%E/>3G$,
M$;22$=E49/\ *N/'Q6\+DL!-<_*0/^/=N<]/\^]"3>PW)+<[>BLO0M>LO$-D
M]W8%S$DAB.]<'<,9_G6I2&@Z]:\C^,%A!$VERP6D2M(TBNZ1X+'*[02!G^(U
MZY7E7QGP;?2A@$AI2/F /\/?K0B9+1E3X-V=K<RZU)+!!.\3P".1XQD*4SQQ
MD#/->L7%G;7-NT$]O%)$1@JZ@BO+?@EM9/$#*,9E@&,8Q^[]*]8;A<T-+F''
M1)'R9=JT;W"QYVJ^W );H0 /U/ZU]3)HVEA!C3;/)'7R%_PKY;U619)+F12,
M/RH8 Y&?\<>M?6*'Y%^E+J$5I\SSSQM\.-(O=)N+RPACLKR%#(64D*Z@'(8#
MVZ<=J\:TC6YO#>H0ZDJ"XC4D7,+@E)HVR&#9P&."I&1V_"OH/QKXFL?#^@W+
M32H;B2,QQ0!\.Q;C..3@9SG%?.5AI<VN:C9Z38J#+?.%.<YC7NQ]L*>?7BK6
MVI$DDU8Z3XA65M;^.+R*QM1'$A5F6$<*Q12> , ]?6O2/@_I%B?A_9W4EG"\
M\\DQ=W4,2!(5 SZ84<5P'Q00)XYO=Q+?-"Q7)QM\M!S[]:]*^#@Q\,M,![--
M_P"CGI.S0XVN[&_XITFQOO#^I>?:Q.XMI&5_+!8$*<$'KVKYWT&W'_"6Z1 \
M):!]5MT9'7<I4MR""3Z =Z^E->)7P]J9! _T64Y]/D-?-_AM3_PEVA1D1ADU
M. ':,#[_ .?4'\Z%H$E>Q])_V-I97_D&V?\ WX7_  KGM<^''A_6+5D2SCM+
M@ F.:$%=IYZ@'!'/2NO%%2U<L^8[ZUU?P1XFV17<D%Y$<"2)^'ZN 1_$#QP:
M]F\):UI_Q"\+A]3L87O;?]U=P21@['QU7/0,.1^7:L+XT:9'_9-KJI528W,3
M@_Q C(_]!(_&N0^#^IFR\;36TV\?VA!)'M!&WS(SOR?^ [L'GK]:K=:D*T78
MXO6P;5]1A0-&$+E!C ^\V!^35],:7X>T1M*M&_LBP^:!"2;9,GY1[5\UZWB2
MXU A4"$R$= QR&()Z=R/:OJ?33LTRT5N&$*#&?84@22OH8'B/P9H^IZ+<0PV
M%M;SA"8Y(8PA#8_V:P_A(WVWP3<Z;?V^Z.VO)(Q'/&3NC;$@SG@_>/Y5,OB_
M4)OBW%X>MY(6TS9()!Y>6W+&&.&^K 5Z!MH19X9\4_"XTG45U*W@9;&X)#LC
M!5C8_P (';/)_2HOA+J-C8>+)K"[B@62]C#6L\@!D$B@AD!ZC<"3_P !->P^
M)=$CU_P_<Z=(%+.N8RP& XY!YSW]J^9]4LKS3M9-LP>&\@F.QA@%& .TY'H2
MO&::U9$E9\R/J+5[ZRT[2;FZU!D6TC0F3>,@CTQWSTQ7B7AK0U\>>+Y[A[5K
M?2()?-N(U<@,#DI&,>XY]OJ*=KOBO5?'UYI?A^TM1$9]C, <Y8 %Y&YX1<Y
M[_I7L'A?P]:^&= M=,MOF\I!YDI&&E?NQ]S1JAZ2-.UM8+.%8;>&.*->BHH
MJ:BBD4%>3?&@QL-'C8#=F5LDGH"@/;'4BO6:\L^,A;R-+QYG67[O /W1@G\1
M0)[$7P4#>7KV<#]Y!E=PR#Y?/&!C_P"M7JYZ5Y-\$1M3Q O)Q/#DD=3L.?UK
MUEONTY?$PB[I'RE<;$GO-\)VEB/EY(XQS^(S^%>AZUH_C70=/&H7.OW,D*N
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28Y*Q(%!. ,\>P _"IZM#/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
